COGT: financial statements from SEC — TradeAlmanac

COGT

Cogent Biosciences, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Sep 30, 2024	Jun 30, 2024
Research and development	75m	69m	62m	63m	64m	54m
Selling, general and administrative	28m	14m	13m	12m	12m	10m
Operating expenses	104m	83m	76m	75m	75m	64m
Operating income	−104m	−83m	−76m	−75m	−75m	−64m
Net income	−97m	−81m	−74m	−72m	−71m	−59m
Earnings per share	−0.53	−0.50	−0.53	−0.52	−0.52	−0.43
Earnings per share, diluted	−0.53	−0.50	−0.53	−0.52	−0.52	−0.43
Weighted average shares	162m	138m	114m	113m	110m	99m
Weighted average shares, diluted	162m	138m	114m	113m	110m	99m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	241m	312m	125m	128m	126m	98m	97m	88m
Current assets	878m	910m	397m

Cash flow

Metric	Mar 31, 2026	Mar 31, 2025
Operating cash flow	−87m	−67m
Depreciation and amortisation	626,000	640,000
Share-based compensation	17m	10m
Capital expenditure	449,000	547,000
Investing cash flow	−36m	69m
Financing cash flow	53m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)